Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

Author(s):

Aleksandra Rachitskaya, MD,Jordan Graff, MD, FACS

Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.

EP: 1.Overview of Novel Treatments for Retinal Vascular Diseases

EP: 2.Overview and Benefits of Port Delivery System with Ranibizumab

EP: 3.Patient Selection for Port Delivery System

EP: 4.Considerations for Surgical Implant of the Port Delivery System and Refill Process

EP: 5.Key Steps in the Surgical Implantation of the Port Delivery System

Now Viewing

EP: 6.Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

EP: 7.Adverse Events of the Port Delivery System and Addressing Challenges With Adoption

EP: 8.Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Video content above is prompted by the following:

Could you discuss the key outcomes from the ARCHWAY trial for PDS?
The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!